Can HMA maintenance therapy improve eligibility for HSCT? - a podcast by Scientific Education Support

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT?

 

Ravandi begins by highlighting the limited maintenance approaches for patients with AML. He continues with the promising results from the QUAZAR AML-001 study evaluating oral azacitidine (CC-486), an oral hypomethylating agent, which can be used for maintenance and to improve eligibility for hematopoietic stem cell transplantation.

---

See acast.com/privacy for privacy and opt-out information.

Further episodes of AML Hub

Further podcasts by Scientific Education Support

Website of Scientific Education Support